Shares of Fulcrum Therapeutics Inc. (FULC) Rise Above Previous 52-Week High

September 21, 2021 11:55:01

Shares of Fulcrum Therapeutics Inc. (NASDAQ:FULC) traded today at $33.00, eclipsing its 52-week high. Approximately 12.2 million shares have changed hands today, as compared to an average 30-day volume of 7 million shares.

Fulcrum Therapeutics Inc. share prices have moved between a 52-week high of $33.00 and a 52-week low of $6.85 and are now trading 367% above that low price at $32.00 per share.

Fulcrum Therapeutics Inc. is a clinical-stage biopharmaceutical company. It has developed a proprietary product engine that employs to identify and validate cellular drug targets that can modulate gene expression. Its product candidate, losmapimod, is a small molecule that was developed for the treatment of FSHD, a muscle-wasting disorder that leads to physical impairments and disability.

Fulcrum Therapeutics Inc. (NASDAQ:FULC) has potential upside of 9.4% based on a current price of $32.00 and analysts’ consensus price target of $35.00.

Receive IBN Spotlights – “Bite Size” Small, Mid and Large-Cap Technical Indicator Alerts
To stay connected with our complimentary IBN Spotlights, please visit

About InvestorBrandNetwork (IBN)
InvestorBrandNetwork (IBN) consists of 50+ trusted financial brands introduced to the investment public over the course of 15+ years. Through these brands, IBN provides (1) access to our Investor Press Release Wire Solutions via InvestorWire (IW) to reach all target markets, industries and demographics in the most effective manner possible; (2) article and editorial syndication to 5,000+ news outlets; (3) enhanced press release solutions via IW to ensure maximum impact; (4) full-scale distribution to an enormous social media audience that includes millions of followers; and (5) a full array of corporate communications solutions focused on the IBN Podcast Series. With a proven track record serving 500+ client partners, IBN is the key to a more effective market communication campaign.

For more information, please visit

Please see full terms of use and disclaimers on the InvestorBrandNetwork website applicable to all content provided by IBN, wherever published or re-published: